BioSyent, Inc. (RX.V)
17.15
+0.23
(+1.36%)
CAD |
TSXV |
Oct 09, 16:00
BioSyent Enterprise Value : 188.68M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 188.68M |
| October 08, 2026 | 186.08M |
| October 07, 2026 | 185.85M |
| October 06, 2026 | 184.71M |
| October 05, 2026 | 185.40M |
| October 02, 2026 | 183.92M |
| October 01, 2026 | 181.31M |
| September 30, 2026 | 183.58M |
| September 29, 2026 | 184.49M |
| September 28, 2026 | 184.49M |
| September 25, 2026 | 177.91M |
| September 24, 2026 | 181.88M |
| September 23, 2026 | 181.77M |
| September 22, 2026 | 192.54M |
| September 21, 2026 | 175.64M |
| September 18, 2026 | 172.58M |
| September 17, 2026 | 176.32M |
| September 16, 2026 | 176.55M |
| September 15, 2026 | 175.42M |
| September 14, 2026 | 173.94M |
| September 11, 2026 | 171.79M |
| September 10, 2026 | 171.67M |
| September 09, 2026 | 172.13M |
| September 08, 2026 | 173.94M |
| September 04, 2026 | 175.30M |
| Date | Value |
|---|---|
| September 03, 2026 | 174.28M |
| September 02, 2026 | 175.64M |
| September 01, 2026 | 174.17M |
| August 31, 2026 | 175.53M |
| August 28, 2026 | 172.81M |
| August 27, 2026 | 175.08M |
| August 26, 2026 | 173.83M |
| August 25, 2026 | 172.24M |
| August 24, 2026 | 169.97M |
| August 21, 2026 | 172.24M |
| August 20, 2026 | 161.47M |
| August 19, 2026 | 161.47M |
| August 18, 2026 | 159.77M |
| August 17, 2026 | 159.77M |
| August 14, 2026 | 167.14M |
| August 13, 2026 | 164.42M |
| August 12, 2026 | 162.03M |
| August 11, 2026 | 164.30M |
| August 10, 2026 | 164.30M |
| August 07, 2026 | 164.30M |
| August 06, 2026 | 169.86M |
| August 05, 2026 | 169.97M |
| August 04, 2026 | 160.33M |
| July 31, 2026 | 161.47M |
| July 30, 2026 | 160.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 167.86M |
| Bausch Health Cos., Inc. | 31.48B |
| Cipher Pharmaceuticals, Inc. | 334.51M |
| Revive Therapeutics Ltd. | 10.94M |
| Knight Therapeutics, Inc. | 988.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.849M |
| Revenue (Quarterly) | 19.87M |
| Total Expenses (Quarterly) | 17.02M |
| EPS Diluted (Quarterly) | 0.245 |
| Gross Profit Margin (Quarterly) | 65.02% |
| Profit Margin (Quarterly) | 14.34% |
| Earnings Yield | 5.00% |
| Operating Earnings Yield | 6.54% |
| Normalized Earnings Yield | 4.998 |